Clinical trials
Phase 2 Arterial Occlusive Diseases trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 2 |
| 2005 | 4 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 2 |
| 2024 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 13 |
| Terminated | 2 |
| Unknown status | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AnGes USA, Inc. | 2 |
| Duke University | 2 |
| ARCA Biopharma, Inc. | 1 |
| AstraZeneca | 1 |
| Beijing Northland Biotech. Co., Ltd. | 1 |
| Fluoropharma, Inc. | 1 |
| Johann Wolfgang Goethe University Hospital | 1 |
| Merck Sharp & Dohme LLC | 1 |
| Naestved Hospital | 1 |
| POLYSAN Scientific & Technological Pharmaceutical Company | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Arterial Occlusive Diseases | 18 |
| Vascular Diseases | 7 |
| Peripheral Vascular Diseases | 6 |
| Cardiovascular Diseases | 5 |
| Chronic Limb-Threatening Ischemia | 5 |
| Peripheral Arterial Disease | 5 |
| Arteriosclerosis | 4 |
| Coronary Disease | 4 |
| Heart Diseases | 4 |
| Ischemia | 4 |
Trials
Showing 51 to 18 of 18. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.